Cognitive Impairments in Patients with Ischemic Stroke and Their Correction

Евзельман, М. А.; Aleksandrova, Natalya A.

doi:10.1007/s11055-015-0074-z

Cited by 2 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At twelve months, the number of patients with MoCA scores over 26 increased from baseline by 27.5% in favour of Cortexin. Results of MMSE assessment scores were not provided [13] .…”

Section: Resultsmentioning

confidence: 99%

“…Actovegin has been utilized for similar neurological conditions for nearly 50 years [ 8 , 9 ] and is licensed for use in Russia, Eastern European and Asian countries [8] . Cortexin is predominantly prescribed in Russia, where it used to treat a range of acute and chronic neurological disorders including stroke and cognitive impairment [ 10 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…Given the limited therapeutic options to manage VCI, nootropics may represent a promising approach to treating such conditions [7] . While numerous clinical trials have suggested favorable benefit-risk ratios of the animal derived nootropics, available evidence is accompanied by several limitations [ 13 , 8 , 14 – 16 ]. Despite the extensive use of animal-derived nootropics in international healthcare, current evidence regarding their efficacy and safety is conflicting.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis

Alsulaimani

Quinn

2021

Cerebral Circulation - Cognition and Behavior

View full text Add to dashboard Cite

“…At twelve months, the number of patients with MoCA scores over 26 increased from baseline by 27.5% in favour of Cortexin. Results of MMSE assessment scores were not provided [13] .…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis

Alsulaimani

Quinn

2021

Cerebral Circulation - Cognition and Behavior

View full text Add to dashboard Cite

“…[140][141][142] Systematic reviews of dopamine agonists 143 and selective serotonin reuptake inhibitors [144][145][146] show no consistent beneficial effects on cognition after stroke. Individual small clinical trials have reported various pharmaceutical agents that may have a potential benefit on global cognition: neurotrophics (Cortexin), 147 peptides such as Cerebrolysin 148 and relaxin, 149 citicoline (cytidine-5ʹ-diphosphocholine), 150 and nitrates (glyceryl trinitrate). 151 Specific pharmaceuticals may affect defined aspects of cognition, including the effects of dopamine agonists on hemi-inattention 152 and selegiline on attention and executive function.…”

Section: Medical and Pharmacological Treatmentsmentioning

confidence: 99%

Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association

Husseini¹,

Katzan²,

Rost³

et al. 2023

Stroke

105

View full text Add to dashboard Cite

Purpose: Cognitive impairment is a common consequence of stroke and has direct implications for poststroke functioning and quality of life, including the ability to maintain a job, live independently, sustain interpersonal relationships, and drive a vehicle. In this scientific statement, we critically appraise the literature on the prevalence, diagnosis, and management of poststroke cognitive impairment (PSCI) and provide a framework for clinical care while highlighting gaps that merit further study. Methods: We performed a scoping literature review of randomized controlled clinical trials, prospective and retrospective cohort studies, case-control studies, clinical guidelines, review articles, and editorials on the incidence and prevalence, natural history, diagnosis, and management of PSCI. Scoping reviews determine the scope of a body of literature on a given topic to indicate the volume of literature and the studies currently available and provide an overview of its focus. Results: PSCI is common after stroke, especially in the first year, and ranges from mild to severe. Although cognitive impairment is reversible in some cases early after stroke, up to one-third of individuals with stroke develop dementia within 5 years. The pathophysiology is not yet fully elucidated but is likely attributable to an acute stroke precipitating a series of pathological events, often in the setting of preexisting microvascular and neurodegenerative changes. Screening for associated comorbidities and interdisciplinary management are integral components of the care of individuals with PSCI. There is a need for prospective studies evaluating the individual trajectory of PSCI and the role of the acute vascular event in the predisposition for Alzheimer disease and related dementias, as well as high-quality, randomized clinical trials focused on PSCI management.

show abstract

Cognitive Impairments in Patients with Ischemic Stroke and Their Correction

Cited by 2 publications

References 4 publications

The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis

The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis

Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association

Contact Info

Product

Resources

About